Obesity

DEFINITION AND CLASSIFICATION OF OBESITY

  • Definition: Obesity is defined as the excessive accumulation of body mass, specifically adipose tissue, which leads to a significantly higher incidence of chronic disease.

  • BMI Classification Thresholds:

    • Overweight: BMI≥25BMI \ge 25 to 29.9 kg/m229.9\,kg/m^2   

    • Obesity Class I: BMI≥30BMI \ge 30 to <35\,kg/m^2     

    • Obesity Class II: BMI≥35BMI \ge 35 to <40\,kg/m^2     

    • Obesity Class III (Morbid Obesity): BMI≥40 kg/m2BMI \ge 40\,kg/m^2

  • Alternative Metrics: Waist circumference or the waist-to-hip ratio may serve as more accurate indicators of morbidity than BMI alone.

MEDICAL COMPLICATIONS AND SYSTEMIC IMPACT

  • Respiratory System:     

    • Obstructive Sleep Apnea (OSA)

    • Asthma

    • Pulmonary blood clots (Pulmonary Embolism)

    • Lung disease

  • Cardiovascular System:    

    • Heart disease and heart attack

    • Hypertension (High Blood Pressure)

    • Stroke

    • Abnormal lipid profile (Dyslipidemia)

    • Inflamed veins, often occurring with blood clots

  • Metabolic and Endocrine Systems:     

    • Type 2 Diabetes (T2D)

    • Metabolic Syndrome

    • Insulin resistance

  • Gastrointestinal and Hepatic Systems:     

    • Liver disease: Fatty liver (MASLD) and Cirrhosis

    • Gallstones and general Gallbladder disease

    • Pancreatitis

  • Reproductive and Genitourinary Systems:     

    • Women: Abnormal menstrual periods and reduced fertility (infertility)

    • Kidney disease

    • Prostate issues

  • Musculoskeletal and Integumentary Systems:     

    • Osteoarthritis and general Arthritis

    • Gout

  • Oncology (Cancer Risks):     

    • Breast, uterus, colon, esophagus, pancreas, kidney, and prostate

GLOBAL EPIDEMIOLOGY AND TRENDS

  • General Status: Obesity is identified as a leading cause of preventable deaths globally

  • Prevalence by Country (BMI > 30):     

    • Samoa and Tonga: 70%70\%    

    • United States: 41.6%41.6\%     

    • Puerto Rico: 36.5%36.5\%     

    • Mexico: 32%32\%     

    • Guatemala: 23%23\%     

    • France: 10%10\%     

    • Haiti: 6.7%6.7\%     

    • Ethiopia: 2%2\%

  • Temporal Trends (1999–2022): Doubled in adults and quadrupled in adolescents worldwide

ETIOLOGY AND RISK FACTORS

  • Physiological Mechanism: The actual specific physiological mechanism remains unknown.

  • Energy Imbalance: Consuming more calories than are expended.

  • Lifestyle Factors:     

    • Unhealthy eating patterns: High intake of processed foods, high-calorie items, and sugary drinks

    • Lack of physical activity

    • Inadequate sleep, which disrupts hormonal balance

  • Genetics: Genetic factors and family history contribute approximately 3%−15%3\% - 15\% to the risk.

  • Health Conditions and Medications:

    • Estrogens

    • Prednisone (steroids)

    • Antidepressants

  • Environmental Factors:

    • Limited access to high-quality food (food deserts)

    • Lack of safe areas for physical activity.

METABOLIC SYNDROME: DIAGNOSTIC CRITERIA AND IMPLICATIONS

  • Metabolic syndrome:

    • Central obesity

    • Insulin resistance

    • Hypertension

    • Dyslipidemia

    • It poses a significant risk for atherosclerotic cardiovascular diseases and Type II Diabetes Mellitus.

  • Diagnostic Criteria:    

    • At least three of the following five components:     

      • Elevated Waist Circumference: ≥88 cm\ge 88\,cm for women; ≥102 cm\ge 102\,cm for men

      • Elevated Triglycerides: ≥150 mg/dL\ge 150\,mg/dL or undergoing drug treatment for elevated triglycerides

      • Low HDL Cholesterol: < 40\,mg/dL for men; < 50\,mg/dL for women (or drug treatment for low HDL)

      • Elevated Blood Pressure: Systolic ≥130 mm Hg\ge 130\,mm\,Hg OR diastolic ≥85 mm Hg\ge 85\,mm\,Hg (or hypertensive drug treatment)

      • Elevated Fasting Glucose: ≥100 mg/dL\ge 100\,mg/dL or drug treatment for elevated glucose

PREVENTION AND MANAGEMENT STRATEGIES

  • Conservative Prevention:

    • Diet

    • Physical activity

    • Adequate sleep

    • Reduction of alcohol

    • Smoking cessation

  • Weight Loss Management:     

    • Diet:

      • Very low-calorie diets offer rapid loss but are unsustainable

      • High-protein/low-carb/ketogenic diets, Jenny Craig, and Weightwatchers have shown success for moderate loss.     

    • Physical Activity:

      • Should start slowly and remain consistent

      • Aiming for approximately 150 min/week150\,\text{min/week} or more

    • Behavioral Therapy: Addressing the patient's psychological relationship with food

    • Medications: Utilized for BMI≥30 kg/m2BMI \ge 30\,kg/m^2 or when lifestyle changes fail

    • Bariatric Surgery: Generally reserved for BMI > 35 with comorbidities or for the most difficult cases.

PHARMACOLOGICAL TREATMENTS AND MECHANISMS

  • Semaglutides (e.g., Ozempic, Wegovy, Rybelsus):    

    • Mechanism: Glucagon-like peptide-1 (GLP-1) receptor agonists. They reduce total fat mass and regional visceral fat mass while increasing lean body mass. They modulate insulin and lipid pathways.    

    • Efficacy: Highly effective for weight loss (15%−18%15\% - 18\%) and Non-Insulin Dependent Diabetes Mellitus (NIDDM)

    • Side Effects: Primarily gastrointestinal (Nausea, Vomiting, Diarrhea—NVD), headache, and fatigue.     

    • Administration: Wegovy and Ozempic are weekly subcutaneous injections; Rybelsus is the oral form (noted as slightly less effective than injections in trials).

  • Tirzepatide (e.g., Zepbound, Mounjaro):     

    • Mechanism: Dual action binding to both GLP-1 and GIP (Glucose-dependent insulinotropic polypeptide) receptors

    • Efficacy: Clinical trials suggest it may be slightly more effective for weight loss than semaglutide alone.

  • Orlistat:     

    • Mechanism: Gastric and pancreatic lipase inhibitor. It blocks the breakdown of fats, causing most dietary fat to pass as fatty feces (steatorrhea).    

    • Side Effects: Flatulence, fecal urgency, oily stools, and potential malabsorption of fat-soluble vitamins.

  • Liraglutide: A GLP-1 receptor agonist administered via daily subcutaneous injection, resulting in approximately 5%−6%5\% - 6\% weight loss.

  • Phentermine/Topiramate-ER: A combination of a sympathomimetic amine and a gabaminergic drug. Causes 9%−10%9\% - 10\% weight loss. Contraindicated in glaucoma and hyperthyroidism.

  • Naltrexone-ER/Bupropion-ER: An opioid-receptor antagonist and dopamine-norepinephrine reuptake inhibitor. Causes 4%−6%4\% - 6\% weight loss.

PHYSIOLOGY OF INCRETIN HORMONES: GLP-1 AND GIP

  • GLP-1 (Glucagon-like peptide-1):     

    • Source: Secreted by enteroendocrine L-cells in the distal small intestine and colon

    • Functions: Stimulates glucose-dependent insulin secretion, suppresses glucagon, significantly slows gastric emptying (increasing satiety), and reduces appetite

    • Degradation: Half-life of 1−2 minutes1 - 2\,\text{minutes}, degraded by dipeptidyl peptidase-4 (DPP-4)

  • GIP (Glucose-dependent insulinotropic polypeptide):    

    • Source: Secreted by K-cells in the proximal small intestine (duodenum/jejunum)

    • Functions: Potent stimulator of insulin secretion, promotes lipid storage/lipogenesis in adipose tissue, and stimulates glucagon during hypoglycemia to balance blood glucose

    • Bone Health: Promotes bone formation by stimulating osteoblast proliferation.

  • Joint Roles: Combined, they account for 50%−70%50\% - 70\% of total postprandial insulin secretion (the "Incretin Effect") and support pancreatic β\beta-cell survival.

BARIATRIC SURGICAL INTERVENTIONS

  • Roux-en-Y Gastric Bypass:

    • Most common major surgery

    • Involves bypassing the stomach, duodenum, and part of the jejunum to reduce calorie absorption

    • Higher risk but high efficacy

  • Adjustable Gastric Banding: A less invasive procedure with a lower likelihood of nutritional deficiencies

  • Vertical Sleeve Gastrectomy (VSG): Removal of a large portion of the stomach

  • Biliopancreatic Diversion with a Duodenal Switch (BPD-DS): A more complex procedure involving both restrictive and malabsorptive components

  • Clinical Implications: Post-operative care must prioritize pain control and rigorous nutrition monitoring due to malabsorption risks

NURSING CARE: THE 5As OF OBESITY COMMUNICATION

  • 1. Ask: Seek permission to discuss weight and determine the patient's readiness for change.

  • 2. Assess: Identify obesity class, check for medical complications, and uncover barriers to change.

  • 3. Advise: Educate on the benefits of even modest weight loss, discuss long-term strategies, and explore treatment options.

  • 4. Agree: Collaborate on realistic weight loss goals, behavioral targets, and a comprehensive treatment plan.

  • 5. Assist: Provide education, connect the patient with resources/specialists, and ensure appropriate follow-up.